GQR’s Post

emovis joined FutureMeds - this is what happened: Building on our DCT expertise and HomeCare Visits service, FutureMeds became the 1st European Dedicated DCT Site Network. Combining our organisations' expertise, resources, and solutions means that CROs can: - Rely on our site and PI insights to shape strategy and novel trial designs,  - Boost diversity & inclusion, and patient experience,  - Access larger suitable patient populations,  - Strengthen patient retention rates,  - Improve the flow of information - Achieve higher compliance, and - Generate quality data And our track record of over 9,000 patients recruited in over 250 studies across 120 indications proves we deliver effective solutions. As part of FutureMeds, our team will amplify the value we deliver to our clients and patients. We are proud to be part of a site network with growing influence. -- P.S. On the 28th of November, we will shift our activities to  FutureMeds. Follow us for updates there. #ClinicalResearch #ClinicalTrials #DCT 

A new chapter in our professional life begins today. New colleagues, new opportunities, new geographies, but same enthusiasm, commitment, passion and love for this work. #TeamIntexo #MarketAccess #ScientificRegulatory #TogetherStronger Intexo Società Benefit ProductLife Group

Happening Today: The Integration of Clinical Trials and Clinical Care: A Revolution in the Participant and Sponsor Experience or an Implementation Nightmare? Or Both? Join Gerald E. Finken and Jeanne Hecht for this session at #PharmSci360 https://cdmcd.co/XKkD55

Medscape’s latest episode in our ground-breaking Change Makers series is John Whyte’s interview with Elcin Barker Ergun, Menarini’s CEO in Florence, Italy. Elcin and John discuss the role of precision medicine, diagnostics, AI in healthcare, leadership style and how the decision making process is often different in Europe vs other regions.  #changemakers #menarini #medscape #leadership

Watch our CEO Elcin Barker Ergun speaking on Menarini’s transformation, what makes Menarini unique and various aspects of leadership. In a industry where there are few women leaders it’s wonderful to be led by a dynamic woman changemaker. It’s wonderful to be part of this transformation! #menarini #transformation #renaissanceinhealthcare #leadershiptalk #changemaker #wearemenarini

The commercial future of DTx? Join us for a timely DHV Leaders Club round table event with two industry insiders. At DHV-NET, there were long standing concerns about the viability of some business models in #digitaltherapeutics and so in March 23, we held an event entitled "Should you invest in DTx?". This was a very lively affair with superb insight from our expert guests John Grumitt, Pilar Fernandez Hermida and Dr Richard Pratt, stimulating a great deal of discussion amongst our delegation. Shortly after, adverse headlines started to appear but in recent weeks, there has perhaps been more optimistic news. This appears to be a critical juncture for DTx and there is now history to learn from in the sector. With this in mind, we'll look forward to a fascinating session with Chris Wasden from Twill and Martha Carruthers from Avegen. As #GTM strategy is "my thing" in terms of consulting duties, I'll really be looking forward to this one. - The DHV Leaders Club session on Oct 20th is "the future role of pharma in #digitalhealth". We have picked up on some pharma backing away from the digital health space but looking back, pharma has proved to be a life line for DTx start-ups. How will this play out? - A few days before on Sept 12th we'll create a vision of AI-empowered healthcare in 2026. How will the "sudden rise" of AI affect the DTx sector? - As ever geography plays an important role. D2C appear to have been challenging in Europe and the US but more recently there have been signs of success in Asia. - How will prescription DTx play out particularly given the rise of national reimbursement schemes in Europe and the struggles of companies that have entered this space? - Is DTx a useful label? Controversial perhaps but from a GTM perspective each individual business is unique and does a generic label that's increasingly difficult to define add any value? It might be useful when fund raising but does this label help or hinder in the commercial process? #digitalhealth is a fascinating and often counterintuitive space; post-covid, mid-slump but with unprecedented pressure on our sick care systems, this is a critical moment. Links in comments. Non-members one free pass per season.

Medscape’s latest episode in our ground-breaking Change Makers series is John Whyte’s interview with Elcin Barker Ergun, Menarini’s CEO in Florence, Italy. Elcin and John discuss the role of precision medicine, diagnostics, AI in healthcare, leadership style and how the decision making process is often different in Europe vs other regions. #changemakers #menarini #medscape #leadership

💡Don't miss our Fireside Chat at DTx East. Daniel Gewecke Daugaard will address the key questions we face in bringing the value of digital health solutions to more people living with chronic diseases. #codetosavelives #dtxeast

Announcing Our New Unified Social Media Presence! We are thrilled to share that Med Pharm and Med Doc are merging our social media pages to better serve you. Follow us at Med Doc & Med Pharm Recruitment for the latest updates on healthcare recruitment, industry insights, and more. We look forward to continuing our journey together on this streamlined platform. #HealthcareTogether #MedDoc

Looking forward to this session, leapfrogging technology to bring transformational health impact for LMICs! Please join the discussions and reach out to me when you are around, #datasolidarity #healthequity PharmAccess